China Resources Pharmaceutical Group Limited

SEHK:3320 Rapporto sulle azioni

Cap. di mercato: HK$34.1b

China Resources Pharmaceutical Group Crescita futura

Future criteri di controllo 2/6

China Resources Pharmaceutical Group prevede che gli utili e i ricavi cresceranno rispettivamente di 6.8% e 7.9% all'anno. Si prevede che l'EPS crescerà di 7.5% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 5.9% in 3 anni.

Informazioni chiave

6.8%

Tasso di crescita degli utili

7.5%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili11.1%
Tasso di crescita dei ricavi7.9%
Rendimento futuro del capitale proprio5.9%
Copertura analitica

Good

Ultimo aggiornamento13 Dec 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?

Dec 19
Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?

China Resources Pharmaceutical Group Limited's (HKG:3320) Shares Climb 34% But Its Business Is Yet to Catch Up

Oct 07
China Resources Pharmaceutical Group Limited's (HKG:3320) Shares Climb 34% But Its Business Is Yet to Catch Up

Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

Aug 30
Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

Jun 01
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%

May 13
Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%

China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697

Apr 28
China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697

China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

Apr 14
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697

Mar 28
China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697

China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon

Jan 28
China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon

We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt

Dec 06
We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt

Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?

Sep 07
Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?

Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?

Aug 02
Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?

With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case

May 26
With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case

These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

May 05
These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year

Apr 04
China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year

Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?

Jan 24
Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?

Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?

Dec 15
Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?

China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price

Oct 18
China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price

China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt

Aug 27
China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt

China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15

May 29
China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15

China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15

May 02
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15

China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's

Apr 07
China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's

China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet

Mar 31
China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet

Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?

Feb 21
Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?

Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

Dec 07
Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate

Nov 10
China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate

These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

Aug 29
These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?

Aug 03
Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?

Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?

May 03
Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?

Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?

Apr 12
Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?

Previsioni di crescita degli utili e dei ricavi

SEHK:3320 - Stime future degli analisti e dati finanziari passati (CNY Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/2026319,0405,12210,67816,9777
12/31/2025292,6974,7437,79912,3449
12/31/2024266,1474,3197,28216,6409
6/30/2024250,4833,77715,27818,300N/A
3/31/2024247,5933,81613,91416,925N/A
12/31/2023244,7043,85412,55015,550N/A
9/30/2023232,5643,57310,22312,883N/A
6/30/2023224,6563,3827,69710,053N/A
3/31/2023224,5873,5187,84710,355N/A
12/31/2022218,1833,5008,23910,821N/A
9/30/2022221,4873,7247,43110,371N/A
6/30/2022211,7883,7196,2409,347N/A
3/31/2022196,2263,2886,9359,628N/A
12/31/2021193,0213,0728,00910,468N/A
9/30/2021191,4952,8695,9588,155N/A
6/30/2021187,5542,6263,7925,694N/A
3/31/2021179,5122,7204,5216,344N/A
12/31/2020168,7622,7765,1946,910N/A
9/30/2020171,8732,6836,9868,696N/A
6/30/2020174,9562,5788,91410,616N/A
3/31/2020181,0542,7937,2729,038N/A
12/31/2019182,6902,9375,4887,274N/A
9/30/2019183,4173,6705,6587,406N/A
6/30/2019173,9384,1875,5107,124N/A
3/31/2019165,6793,7375,3706,990N/A
12/31/2018166,6263,4945,5287,244N/A
9/30/2018163,7343,4664,9846,419N/A
6/30/2018154,8523,3094,2765,387N/A
3/31/2018142,2962,959N/A4,493N/A
12/31/2017143,6882,901N/A4,045N/A
9/30/2017143,2522,759N/A1,486N/A
6/30/2017142,2762,602N/A-1,189N/A
3/31/2017142,0032,577N/A1,219N/A
12/31/2016140,3162,526N/A3,689N/A
9/30/2016132,2532,161N/A4,391N/A
6/30/2016129,3131,889N/A5,222N/A
3/31/2016123,7702,103N/A5,027N/A
12/31/2015122,7852,388N/A5,017N/A
12/31/2014108,5752,116N/A3,349N/A
12/31/201391,3132,061N/A3,203N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di 3320 ( 6.8% all'anno) è superiore al tasso di risparmio ( 2.3% ).

Guadagni vs Mercato: Si prevede che gli utili di 3320 ( 6.8% all'anno) cresceranno più lentamente rispetto al mercato Hong Kong ( 11.6% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di 3320 cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di 3320 ( 7.9% all'anno) crescerà più rapidamente del mercato Hong Kong ( 7.8% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di 3320 ( 7.9% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di 3320 sarà basso tra 3 anni ( 5.9 %).

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2024/12/23 09:19
Prezzo dell'azione a fine giornata2024/12/23 00:00
Guadagni2024/06/30
Guadagni annuali2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .

Fonti analitiche

China Resources Pharmaceutical Group Limited è coperta da 20 analisti. 9 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Bo LiBofA Global Research
Shun Kei LawCCB International Securities Limited
Zhishun SiuCCB International Securities Limited